The CD3-Zeta Chimeric Antigen Receptor Overcomes TCR Hypo-Responsiveness of Human Terminal Late-Stage T Cells

Adoptive therapy of malignant diseases with tumor-specific cytotoxic T cells showed remarkable efficacy in recent trials. Repetitive T cell receptor (TCR) engagement of target antigen, however, inevitably ends up in hypo-responsive cells with terminally differentiated KLRG-1(+) CD57(+) CD7(−) phenot...

Descripción completa

Detalles Bibliográficos
Autores principales: Rappl, Gunter, Riet, Tobias, Awerkiew, Sabine, Schmidt, Annette, Hombach, Andreas A., Pfister, Herbert, Abken, Hinrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3264628/
https://www.ncbi.nlm.nih.gov/pubmed/22292024
http://dx.doi.org/10.1371/journal.pone.0030713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3264628/
https://www.ncbi.nlm.nih.gov/pubmed/22292024
http://dx.doi.org/10.1371/journal.pone.0030713

Ejemplares similares